Even though the company’s profit, revenue and profitability exceeded expectations, brokerages feel that the growth in recent quarters was fuelled by the spectacular sales of Revlimid. They say the contribution from the drug will soon start waning out, and many still retain their ‘hold’ and ‘sell’ calls.